These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9406474)
1. [Importation in France of drugs without authorization for marketing]. Blanc P Ann Pharm Fr; 1997; 55(5):232-5. PubMed ID: 9406474 [TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
3. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
4. [Regulations on gases for medical use in France]. Poitou P; Fouret C; Duffau E Ann Pharm Fr; 2002 Sep; 60(5):326-32. PubMed ID: 12378142 [TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
6. [The precautionary principle, research and drugs]. Joly P Bull Acad Natl Med; 2000; 184(5):931-6. PubMed ID: 11077714 [TBL] [Abstract][Full Text] [Related]
8. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Olivier P; Montastruc JL Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082 [TBL] [Abstract][Full Text] [Related]
9. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research]. Jaillon P Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783 [TBL] [Abstract][Full Text] [Related]
10. [Self-medication: Is regulation needed...from whom?]. Caulin C; Cranz H Therapie; 2000; 55(4):547-53. PubMed ID: 11098734 [TBL] [Abstract][Full Text] [Related]
11. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives. Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428 [TBL] [Abstract][Full Text] [Related]
12. [Difficulties with conducting clinical trials in France]. Zannad F; Plétan Y Therapie; 2001; 56(4):341-7. PubMed ID: 11677850 [TBL] [Abstract][Full Text] [Related]
13. [Antidepressants consumption in the global population in France]. Olié JP; Elomari F; Spadone C; Lépine JP Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542 [TBL] [Abstract][Full Text] [Related]
14. Control of product batches (before and after registration). The French approach. Vannier P Dev Biol Stand; 1992; 79():179-82. PubMed ID: 1286755 [TBL] [Abstract][Full Text] [Related]
16. [Drug evaluation: new requirements and perspectives]. Addis A; Rocchi F Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718 [TBL] [Abstract][Full Text] [Related]
17. What criteria for pharmaceuticals reimbursement? An empirical analysis of the evaluation of "medical service rendered" by reimbursable drugs in France. Le Pen C; Priol G; Lilliu H Eur J Health Econ; 2003; 4(1):30-6. PubMed ID: 15609166 [TBL] [Abstract][Full Text] [Related]
18. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing]. Mercier C; Bret P; Bret MC; Queuille E Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368 [TBL] [Abstract][Full Text] [Related]
19. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice. Charlton BG Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461 [TBL] [Abstract][Full Text] [Related]